AbbVie struck a three-year deal with the Trump administration, agreeing to lower prices on Medicaid drugs and invest $100bn in US research and manufacturing. The company will receive exemptions from import tariffs and future price controls, aligning with the push to reshore pharmaceutical manufacturing and enhance supply-chain resilience.

The $100bn investment will likely focus on expanding biologics manufacturing capacity and upgrading production technologies. AbbVie’s recent acquisition and modernization of a facility in Arizona hint at how the investment may materialize, with manufacturing scale and reliability becoming strategic assets in the industry.

AbbVie’s agreement with the administration reflects a broader trend among pharmaceutical companies accepting price concessions for tariff relief and regulatory certainty. The deal provides AbbVie flexibility to expand domestic production operations while preserving resources for pipeline development, surpassing its previous $10bn commitment.

The deal expands AbbVie’s US investment plans and joins other major drugmakers in “most-favored-nation” agreements with the administration. These deals focus on targeted price reductions in exchange for tariff relief, shifting US drug pricing negotiations towards domestic manufacturing investment as a key policy factor shaping decisions.

Read more at Yahoo Finance: AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals